stockportfolio.pro
Stocks / ACAD vs EWTX
ACAD vs EWTX
ACADIA Pharmaceuticals Inc. and Edgewise Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ACADIA Pharmaceuticals Inc. (ACAD) | Edgewise Therapeutics, Inc. (EWTX) | |
|---|---|---|
| Market cap | $3.7B | $3.7B |
| Revenue (latest FY) | $1.07B | $0 |
| Net income (latest FY) | $391.00M | $-167.79M |
| Revenue growth (5y CAGR) | 19.4% | — |
| Net margin | 36.5% | — |
| Return on equity | 31.9% | -32.1% |
| P/E ratio | 9.7 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ACAD — free Open EWTX — freeFrequently asked questions
Which is bigger, ACAD or EWTX?
ACADIA Pharmaceuticals Inc. is larger by market capitalization — $3.7B versus $3.7B.
Which grows faster, ACAD or EWTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.